Ramoplanin
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.161.388 |
Chemical and physical data | |
Formula | C119H154ClN21O40 |
Molar mass | 2554.10 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Ramoplanin (INN) is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.[1]
Mechanism
It exerts its bacteriocidal effect by inhibiting cell wall biosynthesis, acting by inhibiting the transglycosylation step of peptidoglycan synthesis.[2]
Uses
Its development has been fast-tracked by the U.S. Food and Drug Administration as a treatment for multiple antibiotic-resistant Clostridium difficile infection of the gastrointestinal tract,[3] Unlike vancomycin, it is absorbed in the gastrointestinal tract, although it is unstable in the bloodstream, so can be taken only orally against Clostridium difficile infections of the gastrointestinal tract.[4][5][6]
References
- ↑ Farver DK, Hedge DD, Lee SC (May 2005). "Ramoplanin: a lipoglycodepsipeptide antibiotic". The Annals of Pharmacotherapy. 39 (5): 863–8. doi:10.1345/aph.1E397. PMID 15784805. S2CID 6026698.
- ↑ Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S (January 2006). "The mechanism of action of ramoplanin and enduracidin". Molecular BioSystems. 2 (1): 69–76. doi:10.1039/b515328j. PMID 16880924.
- ↑ Fulco P, Wenzel RP (December 2006). "Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent". Expert Review of Anti-Infective Therapy. 4 (6): 939–45. doi:10.1586/14787210.4.6.939. PMID 17181409. S2CID 12881565.
- ↑ Scheinfeld N (January 2007). "A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus". Journal of Drugs in Dermatology. 6 (1): 97–103. PMID 17373167.
- ↑ Balagopal A, Sears CL (October 2007). "Clostridium difficile: new therapeutic options". Current Opinion in Pharmacology. 7 (5): 455–8. doi:10.1016/j.coph.2007.05.007. PMID 17644040.
- ↑ Gerding DN, Muto CA, Owens RC (January 2008). "Treatment of Clostridium difficile infection". Clinical Infectious Diseases. 46 Suppl 1: S32-42. doi:10.1086/521860. PMID 18177219.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.